Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) has announced an inducement grant for a new employee under its 2017 Inducement Plan. The Compensation Committee approved non-qualified stock options to purchase 30,000 shares of common stock at an exercise price of $3.83 per share, matching Adverum's closing price on the grant date.
The stock options will vest over a four-year period, with 25% vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months, contingent on the employee's continued service with Adverum. The grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM) ha annunciato un'indennità per un nuovo dipendente ai sensi del suo Piano di Indennità del 2017. Il Comitato per la Retribuzione ha approvato opzioni su azioni non qualificate per l'acquisto di 30.000 azioni ordinarie a un prezzo di esercizio di $3,83 per azione, corrispondente al prezzo di chiusura di Adverum nella data di concessione.
Le opzioni su azioni matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e le azioni rimanenti che maturano mensilmente a 1/48 nel successivo periodo di 36 mesi, a condizione che il dipendente continui a lavorare con Adverum. La concessione è stata approvata in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM) ha anunciado una concesión de incentivo para un nuevo empleado bajo su Plan de Incentivos de 2017. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 30,000 acciones ordinarias a un precio de ejercicio de $3.83 por acción, que coincide con el precio de cierre de Adverum en la fecha de concesión.
Las opciones sobre acciones se consolidarán durante un período de cuatro años, con el 25% consolidándose después del primer año y las acciones restantes consolidándose mensualmente a 1/48 durante los siguientes 36 meses, sujeto a la continuidad del servicio del empleado con Adverum. La concesión fue aprobada de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM)는 2017년 유인 계획에 따라 새로운 직원에게 유인 보조금을 발표했습니다. 보상위원회는 30,000주의 보통주를 주당 $3.83의 행사가격으로 구매할 수 있는 비자격 주식 옵션을 승인했습니다. 이는 보조금이 지급된 날의 Adverum의 종가와 일치합니다.
주식 옵션은 4년에 걸쳐 분할 지급되며, 첫 해에 25%가 분할 지급되고 나머지 주식은 이후 36개월 동안 매월 1/48씩 분할 지급됩니다. 이는 직원이 Adverum에서 계속 근무하는 것을 조건으로 합니다. 이 보조금은 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
Adverum Biotechnologies (NASDAQ: ADVM) a annoncé une subvention d'incitation pour un nouvel employé dans le cadre de son Plan d'Incitation de 2017. Le Comité de Rémunération a approuvé des options d'achat d'actions non qualifiées pour acheter 30 000 actions ordinaires à un prix d'exercice de 3,83 $ par action, correspondant au prix de clôture d'Adverum à la date de la subvention.
Les options d'achat d'actions acquerront des droits sur une période de quatre ans, avec 25 % acquérant des droits après la première année et les actions restantes acquérant des droits mensuellement à raison de 1/48 au cours des 36 mois suivants, sous réserve de la continuité du service de l'employé avec Adverum. La subvention a été approuvée conformément à la règle de cotation Nasdaq 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM) hat einen Anreizzuschuss für einen neuen Mitarbeiter im Rahmen seines Anreizplans von 2017 angekündigt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 30.000 Aktien zu einem Ausübungspreis von 3,83 $ pro Aktie, was dem Schlusskurs von Adverum am Tag der Gewährung entspricht.
Die Aktienoptionen werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach dem ersten Jahr fällig werden und die verbleibenden Aktien in den folgenden 36 Monaten monatlich zu 1/48 fällig werden, vorausgesetzt, der Mitarbeiter bleibt weiterhin bei Adverum tätig. Der Zuschuss wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
What are the terms of Adverum's (ADVM) latest stock option grant?
How does the vesting schedule work for ADVM's new inducement grant?
What was the exercise price for Adverum's (ADVM) April 2025 inducement grant?
Under which plan was ADVM's new employee stock option grant issued?
